Skip to main content
×
Home
    • Aa
    • Aa

Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus

  • A. Luque (a1), S. Hulse (a1), D. Wang (a2), U. Shahzad (a1) (a3), E. Tanzman (a4), S. Antenozzi (a4) and B. Smith (a4)...
Abstract
Objective.

To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).

Methods.

Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.

Setting.

University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.

Participants.

Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.

Results.

We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.

Conclusion.

Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

Copyright
Corresponding author
University of Rochester Medical Center, Box 689, 601 Elmwood Ave., Rochester, NY 14642 (amneris_luque@urmc.rochester.edu)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2. V DeGruttola , GR Seage III, KH Mayer , et al.Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989;42:849856.

3. B Varghese , JE Maher , TA Peterman , BM Branson , RW Steketee . Reducing the risk of sexual HIV transmission: quantifying the per-act risk for HIV on the basis of choice of partner, sex act, and condom use. Sex Transm Dis 2002;29:3843.

4.European Study Group. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992;304:809813.

5. K Page-Shafer , CH Shiboski , DH Osmond , et al.Risk of HIV attributable to oral sex among men who have sex with men and in the population of men who have sex with men. AIDS 2002;16:23502352.

6. EH Kaplan , R Heimer . HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:175176.

8. DM Cardo , DH Culver , CA Ciesielski , et al.A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:14851490.

9. EM Connor , RS Sperling , R Gelber , et al.Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:11731180.

10. RA Otten , DK Smith , DR Adams , et al.Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000;74:97719775.

12. M Teixeira Garcia , R Morales Figueiredo , ML Moretti , et al.Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis 2005;32:214219.

15. J Balzarmi , Z Hao , P Herdewijn , et al.Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl) adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci 1991;88:14991503.

16. BP Kearny , JF Flaherty , J Shah . Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595612.

17. RT Schooley , P Ruane , RA Myers , et al.Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:12571263.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 1 *
Loading metrics...

Abstract views

Total abstract views: 17 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 29th March 2017. This data will be updated every 24 hours.